For Immediate Release

Company name: DAICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and CEO
(Code no.: 4568, First Section of Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Announcement Regarding the Launch Date in Japan for Memary® 5mg, 10mg and 20mg Tablets for the Treatment of Alzheimer’s Disease

TOKYO, Japan (March 16, 2011) — Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), today announced that it has postponed the launch in Japan of Memary® 5mg, 10mg and 20mg Tablets (generic name: Memantine Hydrochloride) given once daily for the treatment of moderate to severe Alzheimer’s Disease. The launch was scheduled for March 18; however, in order to ensure a stable supply of Memary to patients in light of the March 11 Tohoku Pacific Offshore Earthquake, the launch has been postponed.

Daiichi Sankyo intends to once again move forward with preparations for Memary’s launch as soon as it is possible, and will make an announcement at that time.

###